NASDAQ:EXAS
$67.48
(
3.75%
)
Friday, 27th Jan 2023
EXACT Sciences Corporation Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $45.89 | $70.23 | Friday, 27th Jan 2023 EXAS stock ended at $67.48. This is 3.75% more than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 5.61% from a day low at $64.00 to a day high of $67.59. |
| 90 days | $31.43 | $70.23 | |
| 52 weeks | $29.27 | $84.31 |
Historical EXACT Sciences Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $64.15 | $67.59 | $64.00 | $67.48 | 1 942 472 |
| 2023-01-26 | $65.91 | $66.44 | $63.79 | $65.04 | 1 768 274 |
| 2023-01-25 | $63.53 | $64.31 | $62.27 | $64.25 | 3 146 877 |
| 2023-01-24 | $67.06 | $68.27 | $64.90 | $65.30 | 1 980 237 |
| 2023-01-23 | $68.23 | $69.67 | $67.01 | $67.82 | 1 997 594 |
| 2023-01-20 | $67.20 | $68.45 | $65.01 | $68.23 | 3 125 215 |
| 2023-01-19 | $66.79 | $67.34 | $63.00 | $66.19 | 3 065 400 |
| 2023-01-18 | $68.38 | $70.23 | $67.89 | $67.92 | 2 958 600 |
| 2023-01-17 | $68.17 | $69.18 | $67.10 | $68.38 | 2 841 899 |
| 2023-01-13 | $68.35 | $69.63 | $67.52 | $68.96 | 2 640 224 |
| 2023-01-12 | $67.32 | $68.86 | $64.35 | $68.54 | 4 413 900 |
| 2023-01-11 | $60.50 | $67.21 | $60.24 | $67.20 | 8 424 400 |
| 2023-01-10 | $58.72 | $60.54 | $58.02 | $60.09 | 5 138 948 |
| 2023-01-09 | $55.00 | $60.93 | $53.89 | $58.82 | 10 835 745 |
| 2023-01-06 | $48.98 | $48.98 | $45.89 | $47.19 | 3 151 400 |
| 2023-01-05 | $48.41 | $49.11 | $47.66 | $48.31 | 2 253 489 |
| 2023-01-04 | $48.91 | $50.17 | $48.41 | $48.93 | 1 426 723 |
| 2023-01-03 | $50.54 | $50.79 | $47.65 | $48.20 | 1 627 653 |
| 2022-12-30 | $49.18 | $50.09 | $48.72 | $49.51 | 1 246 762 |
| 2022-12-29 | $49.39 | $51.12 | $48.71 | $49.95 | 1 479 416 |
| 2022-12-28 | $49.39 | $50.14 | $48.66 | $48.80 | 1 547 343 |
| 2022-12-27 | $50.73 | $50.73 | $48.71 | $49.18 | 1 473 944 |
| 2022-12-23 | $53.15 | $53.98 | $50.21 | $50.45 | 1 971 553 |
| 2022-12-22 | $51.25 | $53.18 | $50.81 | $53.15 | 1 812 734 |
| 2022-12-21 | $51.77 | $53.50 | $51.50 | $52.38 | 2 730 624 |
| 2022-12-20 | $49.44 | $52.12 | $49.38 | $51.09 | 2 838 187 |
| 2022-12-19 | $51.61 | $53.32 | $49.44 | $50.00 | 3 227 200 |
| 2022-12-16 | $55.24 | $56.52 | $51.39 | $51.92 | 15 737 769 |
| 2022-12-15 | $44.56 | $45.24 | $43.90 | $44.61 | 2 718 646 |
| 2022-12-14 | $44.77 | $46.80 | $44.33 | $45.54 | 2 158 956 |
| 2022-12-13 | $48.28 | $50.39 | $44.49 | $45.24 | 2 279 121 |
| 2022-12-12 | $44.23 | $46.30 | $44.06 | $45.43 | 1 609 896 |
| 2022-12-09 | $45.70 | $47.00 | $44.54 | $44.60 | 1 260 547 |
| 2022-12-08 | $46.65 | $48.58 | $45.78 | $45.96 | 1 813 839 |
| 2022-12-07 | $45.90 | $46.50 | $45.02 | $45.90 | 1 330 051 |
| 2022-12-06 | $45.45 | $46.34 | $44.67 | $46.18 | 2 009 582 |
| 2022-12-05 | $45.80 | $47.16 | $45.15 | $45.55 | 1 530 226 |
| 2022-12-02 | $44.35 | $46.73 | $43.68 | $46.36 | 1 282 014 |
| 2022-12-01 | $45.00 | $46.78 | $44.78 | $46.00 | 1 455 582 |
| 2022-11-30 | $41.63 | $44.98 | $41.27 | $44.95 | 2 236 977 |
| 2022-11-29 | $41.60 | $42.16 | $40.73 | $41.19 | 1 011 200 |
| 2022-11-28 | $42.23 | $43.23 | $41.08 | $41.50 | 1 250 420 |
| 2022-11-25 | $42.72 | $43.02 | $42.09 | $42.65 | 420 917 |
| 2022-11-23 | $42.08 | $43.32 | $41.75 | $43.09 | 850 397 |
| 2022-11-22 | $42.26 | $42.70 | $41.48 | $42.23 | 784 777 |
| 2022-11-21 | $42.04 | $42.88 | $41.91 | $42.22 | 687 946 |
| 2022-11-18 | $43.92 | $44.13 | $41.91 | $42.34 | 984 109 |
| 2022-11-17 | $42.27 | $43.60 | $41.88 | $42.70 | 1 026 907 |
| 2022-11-16 | $44.10 | $44.52 | $42.65 | $43.65 | 1 038 382 |
| 2022-11-15 | $46.81 | $47.28 | $44.40 | $44.94 | 1 523 285 |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th... EXAS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
